One year following the legalization of cannabis in Germany, public sentiment reveals strong support for controlled sales through pharmacies. A recent YouGov survey indicates that a majority of the population favors this regulated approach, which has contributed to a notable decline in drug offenses.
Dr. Can Ansay, a prominent figure in the pharmacy marketplace, highlights that partial legalization has diminished the black market while ensuring access to high-quality products. The survey, encompassing over 2,000 participants, reflects the views of adults aged 18 and older across Germany.
Data from Stuttgart suggests a slight increase in cannabis consumption post-legalization, with young individuals seeking treatment less frequently, thanks to a shift in the stigma surrounding the drug. However, the ongoing presence of the black market poses challenges, as legal sources remain limited.
The criminal statistics for 2024 illustrate a significant 34.2% decrease in recorded drug offenses, with total cases dropping to 228,104. Despite this progress, the rise in registrations for other substances like cocaine indicates a complex landscape.
The current coalition negotiations threaten to undermine the advancements made in drug policy, highlighting the precarious future of cannabis legalization. Additionally, myths surrounding cannabis, such as its classification as a gateway drug, have been debunked, emphasizing the need for informed discussions about its implications.
Overall, the first year of legalization marks a pivotal moment in Germany's approach to drug policy, balancing public health and safety while confronting ongoing challenges.
